Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

Esketamine was approved for the treatment of treatment-resistant depression in 2019. After the approval of esketamine, numerous concerns have been raised regarding its long-term safety and tolerability. A previous systematic pharmacovigilance study on esketamine-related adverse events (AEs) was publ...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Haoning, Wang, Bin, Yuan, Shuying, Wu, Silin, Liu, Jing, He, Miaoquan, Wang, Jisheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023790/
https://www.ncbi.nlm.nih.gov/pubmed/35462924
http://dx.doi.org/10.3389/fphar.2022.849758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023790/
https://www.ncbi.nlm.nih.gov/pubmed/35462924
http://dx.doi.org/10.3389/fphar.2022.849758

Ejemplares similares